Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.
Pancreatology
; 18(2): 198-203, 2018 Mar.
Article
in En
| MEDLINE
| ID: mdl-29361429
ABSTRACT
INTRODUCTION:
Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty.AIM:
To evaluate sunitinib efficacy and tolerability in panNETs patients treated in a real-world setting. PATIENTS ANDMETHODS:
Retrospective analysis of progressive panNETs treated with sunitinib. Efficacy was assessed by evaluating progression-free survival, overall survival, and disease control (DC) rate (stable disease (SD) + partial response + complete response). Data are reported as median (25th-75th IQR).RESULTS:
Eighty patients were included. Overall, 71.1% had NET G2, 26.3% had NET G1, and 2.6% had NET G3 neoplasms. A total of 53 patients (66.3%) had received three or more therapeutic regimens before sunitinib, with 24 patients (30%) having been treated with four previous treatments. Median PFS was 10 months. Similar risk of progression was observed between NET G1 and NET G2 tumors (median PFS 11 months and 8 months, respectively), and between patients who had receivedâ¯≥â¯3 vsâ¯≤â¯2 therapeutic approaches before sunitinib (median PFS 9 months and 10 months, respectively). DC rate was 71.3% and SD was the most frequent observed response, occurring in 43â¯pts (53.8%). Overall, 59â¯pts (73.8%) experienced AEs, which were grade 1-2 in 43 of them (72.9%), grade 3 in 15â¯pts (25.4%), and grade 4 in one patient (1.7%). Six pts (7.5%) stopped treatment due to toxicity.CONCLUSIONS:
The present real-world experience shows that sunitinib is a safe and effective treatment for panNETs, even in the clinical setting of heavily pre-treated, progressive diseases.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Pyrroles
/
Neuroendocrine Tumors
/
Indoles
/
Antineoplastic Agents
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Humans
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
Pancreatology
Journal subject:
ENDOCRINOLOGIA
/
GASTROENTEROLOGIA
Year:
2018
Document type:
Article
Affiliation country: